サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1703462

カルバマゼピン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年

Carbamazepine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.05円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

カルバマゼピン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

カルバマゼピンの世界市場は、2024年に8,890万米ドルと評価され、2030年には2億1,734万米ドルに達すると予測され、予測期間中に6.80％の複合年間成長率（CAGR）で成長すると予測されています。

同市場は、てんかん、神経障害性疼痛、双極性障害の世界の有病率の増加を主因として、着実に拡大しています。

市場概要
予測期間 2026-2030
市場規模：2024年 8,890万米ドル
市場規模：2030年 2億1,734万米ドル
CAGR：2025年～2030年 6.80%
急成長セグメント ダイレクト
最大市場 アジア太平洋

抗けいれん薬および気分安定薬として定評のあるカルバマゼピンは、てんかん発作性疾患および三叉神経痛の治療の要です。その広範な治療上の有用性と実証された臨床効果により、神経科および精神科医療分野において重要な医薬品として位置づけられています。

競合情勢は、多国籍製薬会社と地域のジェネリック医薬品メーカーで構成されています。これらの市場参入企業は、バイオアベイラビリティの向上、投与回数の削減、副作用の最小化など、製剤の最適化を目指した研究開発に積極的に取り組んでいます。放出制御製剤や徐放性製剤などの革新的製剤は、患者のコンプライアンスと臨床転帰を改善する能力があるため、人気を集めています。

主な市場促進要因

世界のヘルスケアセクターの拡大

主な市場課題

副作用と安全性への懸念

主要市場動向

神経疾患の発生率の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のカルバマゼピン市場に与える影響

第5章 世界のカルバマゼピン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（てんかん、三叉神経痛、双極性障害、糖尿病性神経障害、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のカルバマゼピン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のカルバマゼピン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のカルバマゼピン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のカルバマゼピン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのカルバマゼピン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のカルバマゼピン市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Sthira Labs
  • Jubilant Generics Limited
  • Vemed Pharmaceuticals Private Limited
  • GODAVARI DRUGS LIMITED
  • AKS pharma chem
  • Cipla Limited
  • VARAHI INTERNATIONAL PVT. LTD
  • Sun Pharmaceutical Industries Limited
  • Racs Pharmachem India Pvt.Ltd
  • Sarian Pharmaceuticals Pvt Ltd

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 28243

Global Carbamazepine Market was valued at USD 88.90 million in 2024 and is projected to reach USD 217.34 million by 2030, growing at a compound annual growth rate (CAGR) of 6.80% during the forecast period. The market is witnessing steady expansion, primarily driven by the increasing global prevalence of epilepsy, neuropathic pain, and bipolar disorder.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 88.90 Million
Market Size 2030USD 217.34 Million
CAGR 2025-20306.80%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Carbamazepine, a well-established anticonvulsant and mood stabilizer, remains a cornerstone in the treatment of seizure disorders and trigeminal neuralgia. Its broad therapeutic utility and proven clinical effectiveness have positioned it as a critical pharmaceutical product across neurology and psychiatric care segments.

The competitive landscape comprises both multinational pharmaceutical companies and regional generic drug manufacturers. These market participants are actively engaged in research and development aimed at optimizing drug formulations to enhance bioavailability, reduce dosing frequency, and minimize adverse effects. Innovations such as controlled-release and extended-release formulations have gained traction due to their ability to improve patient compliance and clinical outcomes.

Key Market Drivers

Expansion of the Global Healthcare Sector

The continued growth of the global healthcare industry-generating annual revenues surpassing USD 4 trillion-serves as a significant catalyst for the carbamazepine market. Pharmaceuticals and biotechnology represent the largest segments, contributing approximately USD 850 billion, followed by medical technology and diagnostics at over USD 400 billion.

Enhanced access to healthcare services, improved diagnostic rates, and better treatment infrastructure globally are contributing to the increased demand for carbamazepine. Its role in managing chronic neurological and psychiatric disorders aligns well with the broader shift toward more comprehensive chronic disease management, making it a vital component in modern therapeutic regimens.

Key Market Challenges

Adverse Effects and Safety Concerns

Despite its clinical utility, carbamazepine's long-term use is associated with several adverse effects that may hinder market growth. While the drug continues to be widely prescribed for conditions such as epilepsy, bipolar disorder, and neuropathic pain, its safety profile remains a concern among healthcare professionals and patients.

Common side effects-including dizziness, fatigue, nausea, and impaired coordination-can affect quality of life and patient adherence. More critically, carbamazepine has been linked to rare but severe hypersensitivity reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), particularly among individuals with certain genetic predispositions.

Regulatory agencies, especially in Asia, have introduced mandatory genetic testing (e.g., for the HLA-B*1502 allele) prior to initiating treatment, reflecting growing concerns around safety. While these measures improve patient protection, they can also complicate prescribing protocols and contribute to higher treatment costs.

Key Market Trends

Increasing Incidence of Neurological Disorders

A notable trend influencing the carbamazepine market is the rising global incidence of neurological and psychiatric conditions-including epilepsy, trigeminal neuralgia, and bipolar disorder. The increasing burden of these chronic conditions is fueling demand for reliable and long-term pharmaceutical solutions.

This trend is evident across both developed and developing markets, where advancements in diagnostic technology and growing public health awareness are leading to earlier detection and more comprehensive treatment of neurological disorders. As a result, carbamazepine continues to play a central role in the therapeutic landscape, reinforcing its importance and market potential.

Key Market Players

  • Sthira Labs
  • Jubilant Generics Limited
  • Vemed Pharmaceuticals Private Limited
  • GODAVARI DRUGS LIMITED
  • AKS pharma chem
  • Cipla Limited
  • VARAHI INTERNATIONAL PVT. LTD
  • Sun Pharmaceutical Industries Limited
  • Racs Pharmachem India Pvt.Ltd
  • Sarian Pharmaceuticals Pvt Ltd

Report Scope

In this report, the Global Carbamazepine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbamazepine Market, By Sales Channel:

  • Direct
  • Indirect

Carbamazepine Market, By End Use:

  • Epilepsy
  • Trigeminal Neuralgia
  • Bipolar Disorder
  • Diabetic Neuropathy
  • Others

Carbamazepine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbamazepine Market.

Available Customizations:

Global Carbamazepine Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Carbamazepine Market

5. Global Carbamazepine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Epilepsy, Trigeminal Neuralgia, Bipolar Disorder, Diabetic Neuropathy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Carbamazepine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carbamazepine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Carbamazepine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Carbamazepine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Carbamazepine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Carbamazepine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Carbamazepine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Carbamazepine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Carbamazepine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Carbamazepine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Carbamazepine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carbamazepine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Carbamazepine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Carbamazepine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Carbamazepine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Carbamazepine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Carbamazepine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Carbamazepine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Carbamazepine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Carbamazepine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Carbamazepine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Carbamazepine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Carbamazepine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Carbamazepine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carbamazepine Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sthira Labs
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Jubilant Generics Limited
  • 15.3. Vemed Pharmaceuticals Private Limited
  • 15.4. GODAVARI DRUGS LIMITED
  • 15.5. AKS pharma chem
  • 15.6. Cipla Limited
  • 15.7. VARAHI INTERNATIONAL PVT. LTD
  • 15.8. Sun Pharmaceutical Industries Limited
  • 15.9. Racs Pharmachem India Pvt.Ltd
  • 15.10. Sarian Pharmaceuticals Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer